Charles River (CRL) and CHDI Foundation announced an extension of their ongoing drug discovery partnership into the foreseeable future. The organizations began working together in 2005 to expedite therapeutic development for Huntington’s disease, a genetic neurological disorder that causes the progressive dysfunction of nerve cells in the brain. The extension in 2025, marking the 20-year anniversary of the collaboration, will allow more flexible activity across Charles River’s global network of scientific expertise and provide greater integration into CHDI’s programs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River Labs Extends CEO’s Term Amid Shareholder Meeting
- Deckers downgraded, Morgan Stanley upgraded: Wall Street’s top analyst calls
- Iqvia price target lowered to $188 from $255 at Redburn Atlantic
- Charles River upgraded to Buy from Neutral at Redburn Atlantic
- Ginkgo Bioworks says Steven Coen to replace Mark Dmytruk as CFO